OMNIPAQUE 240 LIQ IV SAR 518MG/ML 240 MG
IODINE (IOHEXOL) : 240 MG · DIN 02018101 · SANOFI CANADA, INC.
Health Canada status: CANCELLED POST MARKET
What is OMNIPAQUE 240 LIQ IV SAR 518MG/ML?
OMNIPAQUE 240 LIQ IV SAR 518MG/ML 240 MG contains IODINE (IOHEXOL) : 240 MG. It is listed in the Health Canada Drug Product Database under DIN 02018101, held by SANOFI CANADA, INC., supplied as LIQUID for SUBARACHNOIDAL ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 30-Jul-1997. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02018101 |
|---|---|
| Brand name | OMNIPAQUE 240 LIQ IV SAR 518MG/ML |
| Generic / active ingredient | IODINE (IOHEXOL) : 240 MG |
| Manufacturer | SANOFI CANADA, INC. |
| Strength | 240 MG |
| Dosage form | LIQUID |
| Route of administration | SUBARACHNOIDAL ; INTRAVENOUS |
| Schedule | Ethical |
| ATC code | V08AB02 IOHEXOL |
| AHFS class | 36:68.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Jul-1997 |
| Original market date | 1985-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code V08AB02 IOHEXOL. 3 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OMNIPAQUE 240 | 518 MG | SOLUTION | GE HEALTHCARE CANADA INC | MARKETED | DIN 02172739 |
| OMNIPAQUE 300 | 647 MG | SOLUTION | GE HEALTHCARE CANADA INC | MARKETED | DIN 02172747 |
| OMNIPAQUE 350 | 755 MG | SOLUTION | GE HEALTHCARE CANADA INC | MARKETED | DIN 02172755 |
| OMNIPAQUE 180 | 388 MG | SOLUTION | GE HEALTHCARE CANADA INC | CANCELLED POST MARKET | DIN 02172720 |
| OMNIPAQUE 180 LIQ SAR 388MG/ML | 180 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02018098 |
| OMNIPAQUE 300 LIQ IV SAR 647MG/ML | 300 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02018128 |
| OMNIPAQUE 350 LIQ IV 755MG/ML | 350 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02018136 |
Who else supplies IOHEXOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IOHEXOL appears in 87 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.